Trending...
- UK Financial Ltd Executes 100% Success Rate on All ERC-3643 Transfers to Coin Holders of MayaCat Regulated Security Token and Maya Preferred PRA
- Sobreseimiento de Nicolás dos Santos y Jorge Méndez expone demandas millonarias a Paraguay y boicot a la Hidrovía
- Color Card Administrator Highlights Growing Enterprise Demand for Operational Infrastructure in Business Card Identity Governance
RALEIGH, N.C., April 16, 2021 /PRNewswire/ -- Contego Medical, Inc., a leading developer of innovative cardiovascular devices, today announced receipt of CE Mark approval for the Neuroguard IEP® 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard IEP System).
The patented Neuroguard IEP System contains a novel, next-generation nitinol stent, a pre-positioned post-dilation balloon and an integrated microembolic filter with 40 μm pores. The closed cell stent is designed to achieve optimal performance across radial strength, vessel coverage and flexibility, additionally featuring a unique asymmetric hourglass design that is flared at both ends to facilitate wall apposition in tortuous anatomy. The integrated filter is designed to capture both macro- and micro-emboli during the entire procedure. The Neuroguard IEP System is indicated for adult patients with clinically significant carotid artery stenosis requiring stenting.
More on ncarol.com
The Neuroguard IEP System was first evaluated in the PERFORMANCE I clinical trial. The study was conducted in nine European sites and included 67 patients with one year follow-up. The overall success rate was 100% with a stroke and death rate of 0% at 30 days1.
"CE Marking of the Neuroguard IEP System is an important milestone for Contego Medical and allows us to bring the remarkable safety and performance benefits of the Neuroguard stent to patients in Europe," said Ravish Sachar, M.D., CEO and Founder of Contego Medical. "We anticipate launching the product in select countries as well initiating a post-marketing clinical study in the coming months."
Stacy Enxing Seng, Venture Partner, Lightstone Ventures, and Contego Medical Board Chair commented "Receipt of CE Mark approval for the Neuroguard IEP System is a significant achievement for the Contego Medical team and represents a multi-year investment in innovative product development and high-quality clinical research. I believe that the Neuroguard IEP System has the performance and ease of use to become the standard of care in the treatment of carotid artery disease."
More on ncarol.com
About Contego Medical
Contego Medical, Inc. is a medical device company dedicated to the development of novel medical devices for cardiovascular and peripheral vascular procedures. The company's Integrated Embolic Protection (IEP) platform, which combines embolic protection and treatment into one device, is designed to simplify catheter-based procedures and improve patient outcomes.
In the United States, the Neuroguard IEP System is an investigational device, limited by United States law to investigational use.
Neuroguard IEP and the Contego Medical logo are registered trademarks of Contego Medical, Inc. The Neuroguard System is covered by U.S. patents 9,968,472 and 10,932,929 and European patent EP 3,367,967. Additional US and Foreign patents pending.
1 LINC 2020
SOURCE Contego Medical, Inc.
The patented Neuroguard IEP System contains a novel, next-generation nitinol stent, a pre-positioned post-dilation balloon and an integrated microembolic filter with 40 μm pores. The closed cell stent is designed to achieve optimal performance across radial strength, vessel coverage and flexibility, additionally featuring a unique asymmetric hourglass design that is flared at both ends to facilitate wall apposition in tortuous anatomy. The integrated filter is designed to capture both macro- and micro-emboli during the entire procedure. The Neuroguard IEP System is indicated for adult patients with clinically significant carotid artery stenosis requiring stenting.
More on ncarol.com
- FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
- AI Velocity Trading Launches Institutional-Grade Algorithmic Engine for Retail Investors
- Speaker and Certified Coach Syrena N. Williams Debuts Powerful New Book on Healing, Identity, and Wholeness
- Adherix Health launches SMS-first retention platform for GLP-1 treatment programs
- Kryptokasinot.io Raises Concerns Over Proposed Cryptocurrency Restrictions in Finland's Gambling Reform
The Neuroguard IEP System was first evaluated in the PERFORMANCE I clinical trial. The study was conducted in nine European sites and included 67 patients with one year follow-up. The overall success rate was 100% with a stroke and death rate of 0% at 30 days1.
"CE Marking of the Neuroguard IEP System is an important milestone for Contego Medical and allows us to bring the remarkable safety and performance benefits of the Neuroguard stent to patients in Europe," said Ravish Sachar, M.D., CEO and Founder of Contego Medical. "We anticipate launching the product in select countries as well initiating a post-marketing clinical study in the coming months."
Stacy Enxing Seng, Venture Partner, Lightstone Ventures, and Contego Medical Board Chair commented "Receipt of CE Mark approval for the Neuroguard IEP System is a significant achievement for the Contego Medical team and represents a multi-year investment in innovative product development and high-quality clinical research. I believe that the Neuroguard IEP System has the performance and ease of use to become the standard of care in the treatment of carotid artery disease."
More on ncarol.com
- New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan
- The Calida Group Announces Sale of Ely at Fort Apache for $57.5 Million
- Bat Cave Flooding Reopens Hurricane Helene Trauma
- Summer Festivals in Gunma Prefecture: Song, Dance, and Vibrant Color – Get There Via Tobu Railway!
- Jetperch Introduces Joulescope JS320 Precision Energy Analyzer for Low-Power Embedded System Development
About Contego Medical
Contego Medical, Inc. is a medical device company dedicated to the development of novel medical devices for cardiovascular and peripheral vascular procedures. The company's Integrated Embolic Protection (IEP) platform, which combines embolic protection and treatment into one device, is designed to simplify catheter-based procedures and improve patient outcomes.
In the United States, the Neuroguard IEP System is an investigational device, limited by United States law to investigational use.
Neuroguard IEP and the Contego Medical logo are registered trademarks of Contego Medical, Inc. The Neuroguard System is covered by U.S. patents 9,968,472 and 10,932,929 and European patent EP 3,367,967. Additional US and Foreign patents pending.
1 LINC 2020
SOURCE Contego Medical, Inc.
Filed Under: Business
0 Comments
Latest on ncarol.com
- How Strategic WooCommerce Development and Digital Marketing Helped a Fashion Ecommerce Business Increase Revenue by 3X
- VIV Welcomes Residents to St. Petersburg's EDGE District
- Evocative Joins the Independent Data Centre Network (IDCN) as Primary USA Operator
- Medical Experts Highlight the Importance of Second Opinions in Death Investigations
- Joseph Nybyk aka Neibich of Gilbert, Arizona
- Omnitronics Unveils 100% Software omniGateDMR and omniGateP25 RoIP Gateways
- KRE PRIME Launches Adaptive Convertible Jumpsuit
- USA Med Bed Helping Home Care Patients with Refurbished Hill Rom Hospital Beds
- Sobreseimiento de Nicolás dos Santos y Jorge Méndez expone demandas millonarias a Paraguay y boicot a la Hidrovía
- CAPHRA warns Southeast Asia not to repeat Australia's nicotine policy failure
- Milo3D.ai Launches Free AI 3D Model Generator That Turns Text and Images Into Game-Ready 3D Assets in Seconds
- UK Financial Ltd Executes 100% Success Rate on All ERC-3643 Transfers to Coin Holders of MayaCat Regulated Security Token and Maya Preferred PRA
- Blank Space: The Unofficial Taylor Swift Tribute Brings Eras Tour Magic To Cities Across America
- Love Must Be the Guide: Live Good Shares a Message of Humanity, Compassion and Hope
- D.R. Crotzer Announces A New Science Fiction Book Series Exploring Life Energy, Dreams, and the Mystery of Existence
- Color Card Administrator Highlights Growing Enterprise Demand for Operational Infrastructure in Business Card Identity Governance
- American Properties Celebrates Grand Opening and Ribbon Cutting Ceremony at Heritage at South
- Crosswalk Ministries USA Announces 2026 Child and Family Well-Being Conference in Stockbridge, Georgia
- Research reveals "The Borderless Pay Standard," a 48-point gap between multinational employers and workers on transparent pay expectations
- Global.ai Appoints Freedomtech Solutions as Specialist Partner for Agentic AI